REVIEW PAPER
Atherosclerosis: a chronic inflammatory disease mediated by mast cells
Submission date: 2014-12-19
Final revision date: 2015-02-26
Acceptance date: 2015-03-27
Publication date: 2015-10-15
Cent Eur J Immunol 2015;40(3):380-386
KEYWORDS
ABSTRACT
Inflammation is a process that plays an important role in the initiation and progression of atherosclerosis and immune disease, involving multiple cell types, including macrophages, T-lymphocytes, endothelial cells, smooth muscle cells and mast cells. The fundamental damage of atherosclerosis is the atheromatous or fibro-fatty plaque which is a lesion that causes several diseases. In atherosclerosis the innate immune response, which involves macrophages, is initiated by the arterial endothelial cells which respond to modified lipoproteins and lead to Th1 cell subset activation and generation of inflammatory cytokines and chemoattractant chemokines. Other immune cells, such as CD4+ T inflammatory cells, which play a critical role in the development and progression of atherosclerosis, and regulatory T cells [Treg], which have a protective effect on the development of atherosclerosis are involved. Considerable evidence indicates that mast cells and their products play a key role in inflammation and atherosclerosis. Activated mast cells can have detrimental effects, provoking matrix degradation, apoptosis, and enhancement as well as recruitment of inflammatory cells, which actively contributes to atherosclerosis and plaque formation. Here we discuss the relationship between atherosclerosis, inflammation and mast cells.
REFERENCES (90)
1.
Rock FL, Hardiman G, Timans JC, et al. (1998): A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A 95: 588-593.
2.
Rosenfeld ME (2013): Inflammation and atherosclerosis: direct versus indirect mechanisms. Curr Opin Pharmacol 13: 154-160.
3.
Parks BW, Lusis AJ (2013): Macrophage accumulation in atherosclerosis. N Engl J Med 369: 2352-2353.
4.
Spirig R, Tsui J, Shaw S (2012): The emerging role of tlr and innate immunity in cardiovascular disease. Cardiol Res Pract 18: 1394.
6.
Gerrity RG, Naito HK (1980): Ultrastructural identification of monocyte-derived foam cells in fatty streak lesions. Artery 8: 208-214.
7.
Zhong Y, Wang X, Ji Q, et al. (2012): CD4+LAP + and CD4 +CD25 +Foxp3 + regulatory T cells induced by nasal oxidized low-density lipoprotein suppress effector T cells response and attenuate atherosclerosis in ApoE-/- mice. J Clin Immunol 32: 1104-1117.
8.
Di Pietro M, De Santis F, Schiavoni G, et al. (2013): Resveratrol in Chlamydia pneumoniae-induced foam cell formation and interleukin-17A synthesis. J Biol Regul Homeost Agents 27: 509-518.
9.
Medzhitov R (2007): Recognition of microorganisms and activation of the immune response. Nature 18: 819-826.
10.
Meier P, Meier R, Blanc E (2008): Influence of CD4+/CD25+ regulatory T cells on atherogenesis in patients with end-stage kidney disease. Expert Rev Cardiovasc Ther 6: 987-997.
11.
Garlanda C, Dinarello CA, Mantovani A (2013): The interleukin-1 family: back to the future. Immunity 39: 1003-1018.
12.
Chen Y, Jian Y, Liu M, et al. (2014): Gr-1CD11b immature myeloid cells (IMC) promote resistance of pro-inflammatory T cells to suppression by regulatory T cells in atherosclerotic Apo E-deficient mice. PLoS One 9: e108620.
13.
Liu DQ, Li LM, Guo YL, et al. (2008): Signal regulatory protein alpha negatively regulates beta2 integrin-mediated monocyte adhesion, transendothelial migration and phagocytosis.
15.
Mallat Z, Tedgui A. (2004): Immunomodulation to combat atherosclerosis: the potential role of immune regulatory cells. Expert Opin Biol Ther 9: 1387-1393.
16.
Norata GD, Marchesi P, Passamonti S, et al. (2007): Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Atherosclerosis 191: 265-271.
17.
Galkina E, Ley K. (2009): Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 27: 165-197.
18.
Li M, Lin J, Wang Z, He S, Ma X, Li D (2010): Oxidized low-density lipoprotein-induced proinflammatory cytokine response in macrophages are suppressed by CD4CD25(+)Foxp3(+) regulatory T cells through downregulating toll like receptor 2-mediated activation of NF-kappaB. Cell Physiol Biochem 25: 649-656.
19.
Meng X, Zhang K, Li J, et al. (2012): Statins induce the accumulation of regulatory T cells in atherosclerotic plaque. Mol Med 18:598-605.
20.
Goldstein JD, Pérol L, Zaragoza B (2013): Role of cytokines in thymus- versus peripherally derived-regulatory T cell differentiation and function. Front Immunol 19: 155.
21.
Iantorno M, Campia U, Di Daniele N, et al. (2014): Gut hormones and endothelial dysfunction in patients with obesity and diabetes. Int J Immunopathol Pharmacol 27433-27436.
22.
Pucino V, De Rosa V, Procaccini C, et al. (2014): Regulatory T cells, leptin and angiogenesis. Chem Immunol Allergy 99: 155-169.
23.
Bobryshev YV, Lord RS (1995): Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of Vascular Dendritic Cells in athero-resistant and athero-prone areas of the normal aorta. Arch Histol Cytol 58: 307-322.
24.
Stoneman V, Braganza D, vvg N, et al. (2007): Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ Res 100: 884-893.
25.
Issekutz AC, Movat HZ (1982): The effect of vasodilator prostaglandins on polymorphonuclear leukocyte infiltration and vascular injury. Am J Pathol 107:300-9.
26.
Pedersen SF, Thrysøe SA, Paaske WP, et al. (2011): Determination of edema in porcine coronary arteries by T2 weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson 13: 52.
27.
Hancock WW, Adams DH, Wyner LR, et al. (1994): CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation, and arterial occlusion after endothelial injury. Am J Pathol 145: 1008-1014.
28.
Inagami T (1994): Atrial natriuretic factor as a volume regulator. J Clin Pharmacol 34: 424-426.
29.
Wang M, Zukas AM, Hui Y, et al. (2006): Eletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. See comment in PubMed Commons belowProc Natl Acad Sci U S A 103: 14507-14512.
30.
Schouten M, Wiersinga WJ, Levi M, et al (2008): Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 83:536-45.
31.
Shin HK, Kim YK, Lee JH, Hong KW (2004): Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 109: 1022-1028.
32.
Muller C, Salvayre R, Nègre-Salvayre A, et al (2011): HDLs inhibit endoplasmic reticulum stress and autophagic response induced by oxidized LDLs. Cell Death Differ 18: 817-828.
33.
Mineo C, Shaul PW (2012): Novel biological functions of high-density lipoprotein cholesterol. Circ Res 111: 1079-1090.
34.
da Rocha RF, De Bastiani MA, Klamt F (2014): Bioinformatics approach to evaluate differential gene expression of M1/M2 macrophage phenotypes and antioxidant genes in atherosclerosis. Cell Biochem Biophys 70: 831-839.
35.
El Hadri K, Mahmood DF, Couchie D, et al (2012): Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis. Arterioscler Thromb Vasc Biol 32:1445-1452.
36.
Madge LA, Pober JS A (2000): A phosphatidylinositol 3-kinase/Akt pathway, activated by tumor necrosis factor or interleukin-1, inhibits apoptosis but does not activate NFkappaB in human endothelial cells. J Biol Chem 275: 15458-15465.
37.
Hughes AD, Clunn GF, Refson J, et al. (1996): Platelet-derived growth factor (PDGF): actions and mechanisms in vascular smooth muscle. Gen Pharmacol 27: 1079-1089.
38.
Alexandru N, Popov D, Dragan E, et al. (2013): Circulating endothelial progenitor cell and platelet microparticle impact on platelet activation in hypertension associated with hypercholesterolemia. PLoS One 8: e52058.
39.
Foks AC, Frodermann V, ter Borg M, et al. (2011): Differential effects of regulatory T cells on the initiation and regression of atherosclerosis. Atherosclerosis 21853-21860.
40.
Yassin LM, Rojas M, Ramírez LA, et al. (2010): Monocyte activation by apoptotic cells removal in systemic lupus erythematosus patients. Cell Immunol 266: 52-60.
41.
Li H, Huang S, Wang S, et al. (2013):Targeting annexin A7 by a small molecule suppressed the activity of phosphatidylcholine-specific phospholipase C in vascular endothelial cells and inhibited atherosclerosis in apolipoprotein E–/–mice. Cell Death Dis 19: e806.
42.
Ren J, Grundy SM, Liu J, et al. (2010): Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: the results of a 15-Year Chinese Multi-Provincial Cohort Study (CMCS). Atherosclerosis 211: 327-332.
43.
Hoff HF, O’Neil J (1988): Extracts of human atherosclerotic lesions can modify low density lipoproteins leading to enhanced uptake by macrophages. Atherosclerosis 70: 29-41.
44.
Falcone C, Bozzini S, Matrone B, et al. (2013): RAGE gene polymorphism in heart failure patients with and without angiographic evidence of significant coronary atherosclerosis. Int J Immunopathol Pharmacol 26: 199-206.
45.
Fukuda S, Horiuchi S, Tomita K, et al (1986): Acetylated low-density lipoprotein is endocytosed through coated pits by rat peritoneal macrophages. Virchows Arch B Cell Pathol Incl Mol Pathol 52: 1-13.
46.
Kritas SK, Caraffa A, Antinolfi P, et al. (2014):IgE Generation and mast cell activation. Eur J Inflamm 12: 21-25.
47.
Kritas SK, Saggini A, Cerulli G, et al. (2014): Relationship between serotonin and mast cells: inhibitory effect of anti-serotonin. J Biol Regul Homeost Agents 28: 377-380.
48.
Kritas SK, Saggini A, Cerulli G, et al. (2014): Neuropeptide NGF mediates neuro-immune response and inflammation through mast cell activation. J Biol Regul Homeost Agents 28: 177-181.
49.
Bot I, Shi GP, Kovanen PT (2015): Mast cells as effectors in atherosclerosis. Arterioscler Thromb Vasc Biol 35: 265-271.
50.
Kritas SK, Saggini A, Varvara G, et al (2013): Impact of mast cells on the skin. Int J Immunopathol Pharmacol 26: 855-859.
51.
Kritas SK, Saggini A, Varvara G, et al. (2013): Mast cell involvement in rheumatoid arthritis. J Biol Regul Homeost Agents 27: 655-660.
52.
Artenjak A, Koželj M, Lakota K, et al. (2013): High avidity anti-2-glycoprotein I antibodies activate human coronary artery endothelial cells and trigger peripheral blood mononuclear cell migration. Eur J Inflamm 11: 385-396.
53.
Shaik-Dasthagirisaheb YB, Varvara G, Murmura G, et al (2013): Vascular endothelial growth factor (VEGF), mast cells and inflammation. Int J Immunopathol Pharmacol 26: 327-335.
54.
Conti P, Varvara G, Murmura G, et al. (2013): Comparison of beneficial actions of non-steroidal anti-inflammatory drugs to flavonoids. J Biol Regul Homeost Agents 27: 1-7.
55.
Bot I, de Jager SC, Bot M, et al. (2010): The neuropeptide substance P mediates adventitial mast cell activation and induces intraplaque hemorrhage in advanced atherosclerosis. Circ Res 106: 89-92.
56.
den Dekker WK, Tempel D, Bot I, et al. (2012): Mast cells induce vascular smooth muscle cell apoptosis via a toll-like receptor 4 activation pathway. Arterioscler Thromb Vasc Biol 32: 1960-1969.
57.
Willems S, Vink A, Bot I, et al (2013): Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events. Eur Heart J 34: 3699-3706.
58.
Frydas S, Varvara G, Murmura G, et al (2013): Impact of capsaicin on mast cell inflammation. Int J Immunopathol Pharmacol 26: 597-600.
59.
Speranza L, Pantalone A, Saggini R, et al. (2013): Inhibitor effect of antioxidant flavonoids quercitin, and capsaicin in mast cell inflammation Eur J Inflamm 11: 353-357.
60.
Galkina E, Ley K (2007): Leukocyte influx in atherosclerosis. Curr Drug Targets 8: 1239-1248.
61.
Kritas SK, Saggini A, Cerulli G, et al (2014): Interrelationship between IL-3 and mast cells. J Biol Regul Homeost Agents 28: 17-21.
62.
Lee M, Calabresi L, Chiesa G, (2002): Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 22: 1475-1481.
63.
Raicevic G, Rouas R, Najar M, et al. (2010): Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Hum Immunol 71: 235-244.
64.
Taub DD, Proost P, Murphy WJ, et al (1995): Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest 95: 1370-1376.
65.
Renne M, Conforti F, Camastra C, et al. (2014): Macrophage activation and patterns of inflammation in obese and non-obese women with breast carcinoma. Eur J Inflamm 12: 197-200.
66.
Haley KJ, Lilly CM, Yang JH, et al. (2000): Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 102: 2185-2189.
67.
Conti P, Pang X, Boucher W, et al. (1997): Impact of Rantes and MCP-1 chemokines on in vivo basophilic cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 89: 4120-4127.
68.
Cipollone F, Marini M, Fazia M, et al. (2001): Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 21: 327-334.
69.
Oliveira SH, Costa CH, Ferreira SH, et al. (2002): Sephadex induces eosinophil migration to the rat and mouse peritoneal cavity: involvement of mast cells, LTB4, TNF-αlpha, IL-8 and PAF. Inflamm Res 51: 144-153.
70.
McNeill E, Iqbal AJ, Patel J, et al. (2014): Contrasting in vitro vs. in vivo effects of a cell membrane-specific CC-chemokine binding protein on macrophage chemotaxis. J Mol Med (Berl) 92: 1169-1178.
71.
Sun J, Sukhova GK, Wolters PJ, et al. (2007): Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 13: 719-724.
72.
Baumruker T, Csonga R, Pursch E, et al. (2003): Activation of mast cells by incorporation of cholesterol into rafts. Int Immunol 15: 1207-1218.
73.
Michel JB (2003): Anoikis in the cardiovascular system: known and unknown extracellular mediators. Arterioscler Thromb Vasc Biol 23: 2146-2154.
74.
Grewal IS, Flavell RA (1998): CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16: 111-135.
75.
Willems S, van der Velden D, Quax PH, et al (2014): Circulating immunoglobulins are not associated with intraplaque mast cell number and other vulnerable plaque characteristics in patients with carotid artery stenosis. PLoS One 9: e88984.
76.
Montero MT, Hernández O, Suárez Y, et al (2000): Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 153: 303-313.
77.
Matusik P, Guzik B, Weber C, Guzik TJ (2012): Do we know enough about the immune pathogenesis of acute coronary syndromes to improve clinical practice? Thromb Haemost 108: 443-456.
78.
Zanin V, Marcuzzi A, Kleiner G, et al (2013): Lovastatin dose-dependently potentiates the pro-inflammatory activity of lipopolysaccharide both in vitro and in vivo. J Cardiovasc Transl Res 6: 981-988.
79.
Barsotti A, Di Napoli P, Taccardi AA, et al. (2001): MK-954 (losartan potassium) exerts endothelial protective effects against reperfusion injury: evidence of an e-NOS mRNA overexpression after global ischemia. Atherosclerosis 155: 53-59.
80.
Vaughan CJ, Gotto AM Jr, Basson CT (2000): The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35: 1-10.
81.
Rajanikant GK, Zemke D, Kassab M, et al. (2007): The therapeutic potential of statins in neurological disorders. Curr Med Chem 14: 103-112.
82.
Weng Z, Zhang B, Asadi S, et al. (2012): Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS One 7: e33805.
83.
Malek HA, Shata A (2014): Effect of a high dose of vitamin D on a rabbit model of atherosclerosis. Int J Immunopathol Pharmacol 27: 195-201.
84.
De Liso F, Bonara P, Vigna L, et al (2013): Oxidative stress and low-grade inflammatory status as cardiometabolic risk factors in Italian occupational overweight/obese subjects. Eur J Inflamm 11: 789-796.
85.
Rickard A, Portell C, Kell PJ, et al. (2005): Protease-activated receptor stimulation activates a Ca2+-independent phospholipase A2 in bladder microvascular endothelial cells. Am J Physiol Renal Physiol 288: F714-F721.
86.
Porreca E, Di Febbo C, Di Sciullo A, et al. (1996): Cysteinyl leukotriene D4 induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia. Thromb Haemost 76: 99-104.
87.
Zardi EM, Sambataro G, Basta F, et al. (2014): Subclinical carotid atherosclerosis in elderly patients with primary Sjögren syndrome: a duplex Doppler sonographic study. Int J Immunopathol Pharmacol 27: 645-651.
88.
Shaik-Dasthagirisaheb YB, Varvara G, Murmura G, et al. (2013): Inhibitor effect of antioxidant flavonoids quercitin, and capsaicin in mast cell inflammation. Eur J Inflamm 11: 353-357.
89.
Yoshino Y, Kohara K, Abe M, et al (2014): Missense variants of the alanine: glyoxylate aminotransferase 2 gene correlated with carotid atherosclerosis in the Japanese population. J Biol Regul Homeost Agents 28: 605-614.
90.
Keum JS, Jaffa MA, Luttrell LM, et al (2014): Novel mechanism of plasma prekallikrein (PK) activation by vascular smooth muscle cells: evidence of the presence of PK activator. J Biol Regul Homeost Agents 28: 587-603.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
